Screener / SEC EDGAR /CIK 0001504776 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Eye Care

Warby Parker Inc. WRBY

Compare with peers Embed
The 10-K against last year's

215 changes: 26 added, 56 removed, 130 reworded, 3 quiet changes

10-K Feb 26, 2026 vs Feb 27, 2025

10-K 0001504776-26-000006 (Feb 26, 2026) vs 10-K 0001504776-25-000010 (Feb 27, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

319 paragraphs · 17 new · 161 reworded · 49 gone · 10-K Feb 26, 2026 against Feb 27, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 158 · 50% changed Every version of it
require us to redesign or rebrand our products, license rights from third parties on potentially unfavorable terms, cease using certain brand names or other intellectual property rights altogether, make substantial payments for royalty or license fees, legal fees, settlement payments or other costs or damages, or admit liability. Such outcomes could encourage others to bring claims against us. To the extent we seek a license to continue offerings or operations found or alleged to infringe third-party intellectual property rights, such a license may be non-exclusive, and therefore our competitors may have access to the same technology licensed to us. In the event we are required to develop alternative, non-infringing infringing technology, this could require significant time (during which we would be unable to continue to offer our affected offerings), effort and expense, and may ultimately not be successful. Any of these events could harm adversely affect our business and cause our results of operations, liquidity, and financial condition to suffer.
Paragraph 15 · 49% changed Every version of it
Meeting customer demand partially depends on our ability to obtain timely and adequate delivery of components for our products and services. We rely on a limited number of third-party suppliers, predominantly outside the United States, for all of the components and materials that go into the manufacturing of our products. We are therefore subject to the risks associated with our suppliers as described under “—We face risks associated with suppliers from whom our products are sourced and are dependent on a limited number of suppliers. suppliers.”
Paragraph 18 · 47% changed Every version of it
We source components from face additional risks related to our international suppliers, especially the optical laboratory we contract with in China and suppliers located in China. China, including port of entry risks such as longshoremen strikes, import restrictions, foreign government regulations, trade restrictions, customs, and duties. In recent years, the U.S. government has implemented tariffs on specified products imported into the United States from China and, as in 2025, the U.S. government announced new or heightened tariffs on product imports from certain countries, including China, Italy, Vietnam and Japan. As a result, there is an increase in costs with respect to our products subject to these tariffs have increased. In February 2025, the U.S. government imposed additional tariffs on imports from China and announced and subsequently paused implementation of tariffs on imports from Canada and Mexico. tariffs. These additional tariffs or any and the threat of future tariffs, as well as a government’s adoption of “buy national” policies or retaliation by another government against such tariffs or policies have introduced significant uncertainty into the market. We Various tariffs enacted in 2025 have implemented mitigation plans been subject to successful legal challenge, but it remains unclear whether and continue to focus on additional mitigation strategies to offset the impact of tariffs, including by continuing to diversify our supplier base in locations outside of China. If we are unable to mitigate the full impact of current and future whom those tariffs or if there is a further escalation of tariffs, costs on a significant portion of our products may increase further, which could reduce our margins or force us to raise prices, and our financial results may be negatively affected. Further increases in China refunded, and the federal government may attempt to impose new or similar tariffs will impact our business, and our financial results may also be impacted by any resulting economic slowdown. under alternative statutory mechanisms.
Paragraph 67 · 46% changed Every version of it
We may also make strategic investments and pursue the acquisition of complementary businesses and technologies rather than through internal development. The identification of suitable investments, alliance partners or acquisition candidates can be difficult, time-consuming, and costly, and we may not be able to successfully complete identified transactions, benefit from such investments or successfully integrate the acquired businesses or technologies. The occurrence of any of these foregoing risks could adversely affect our business, financial condition, and results of operations and expose us to unknown risks or liabilities.
Paragraph 7 · 46% changed Every version of it
We also expect intend to continue invest heavily in growth, but unforeseen expenses or ineffective resource allocation could lead to expend substantial financial and other resources to grow our business, and losses. If we may fail to allocate manage our resources in a manner that results in increased net revenue future growth in our business. Additionally, we may encounter unforeseen operating expenses, difficulties, complications, delays, and other unknown factors that may result in losses in future periods. If our net revenue growth does not meet our expectations in future periods, effectively, our business, financial condition, and results of operations may be harmed, and we may not achieve or sustain profitability in the future.
Paragraph 201 · 44% changed Every version of it
We also source inputs directly from suppliers outside of the United States, including China, Italy, Vietnam, and Japan. Global sourcing and foreign trade involve numerous factors and uncertainties beyond our control including increased shipping costs, the imposition of additional import or trade restrictions, including legal or economic restrictions control. See "—Disruptions to our supply chain can have a material adverse effect on overseas suppliers’ ability to produce our business, financial condition, and deliver inputs, increased custom duties and tariffs including the recent tariffs imposed by the U.S. government, unforeseen delays in customs clearance of goods, more restrictive quotas, loss of a most favored nation trading status, currency exchange rates, transportation delays, port of entry issues and foreign government regulations, political instability and wars, and economic uncertainties in the countries from which we or our suppliers source our products. Our sourcing operations may also be hurt by health concerns regarding infectious diseases in countries in which our inputs are produced. operating results.” Moreover, negative press or reports about internationally sourced inputs may sway public opinion, and thus customer confidence, away from the products sold in our stores. These and other issues affecting our international suppliers or internationally sourced inputs could have a material adverse effect on our business, financial condition, and results of operations.
Paragraph 205 · 44% changed Every version of it
We rely on a limited number of third-party suppliers and contract manufacturers for the components that go into the manufacturing of our products. In particular, over around half of the cellulose acetate used to produce our frames is provided by a single supplier. We also assemble and fulfill glasses at our optical laboratories as well as at a limited number of third-party optical laboratories. Further, we rely on a single logistics partner to fulfill orders for our Home Try-On program and a limited number of other logistics partners to transport and deliver our products. Our reliance on a limited number of contract manufacturers and logistics partners for our products increases our risks of being unable to deliver our products in a timely and cost-effective manner. In the event of interruption from any of our contract manufacturers or our own fulfillment capabilities, we may not be able to increase capacity from other sources or develop alternate or secondary sources without incurring material additional costs and substantial delays. Our business could be adversely affected if one or more of our manufacturers is impacted by a natural disaster, an infectious disease outbreak or similar public health crisis, or other interruption at a particular location.
Paragraph 173 · 44% changed Every version of it
Companies are required to report certain voluntary recalls and corrections to FDA and to maintain certain records of recalls and corrections that are not reportable to the FDA. We or adequately address problems associated with our third-party manufacturers products, we may initiate voluntary withdrawals or corrections for our products that we or our third-party manufacturers determine do not require notification of the FDA. If the FDA disagrees with such determinations, it could require the relevant manufacturer to report those actions as recalls and levy face additional regulatory enforcement action. A future recall announcement could harm our reputation with customers, potentially lead to product liability claims against us and negatively affect our sales. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract management from operating our business, and may harm our reputation and financial results.

MD&A

100 paragraphs · 9 new · 39 reworded · 7 gone · 10-K Feb 26, 2026 against Feb 27, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 47 · 50% changed
We primarily derive revenue from the sales of eyewear products, optical services eyewear, contact lenses, and accessories. eye care. We sell products and services through our stores, website, and mobile apps. Revenue generated from eyewear includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, lens replacements, and customer charges for optional expedited shipping. Revenue generated from vision care consists of in-person eye exams and prescriptions issued through the Virtual Vision Test app. Revenue from products is recognized when the customer takes possession of the product, either at the point of delivery or in-store pickup, and is recorded net of returns and discounts. Revenue for services is recognized when the service is rendered and is recorded net of discounts.
Paragraph 42 · 38% changed
(4) (3) Represents internal and external non-capitalized costs related to the implementation of our major new Enterprise Resource Planning (“ERP”) system. enterprise software systems.
Paragraph 55 · 33% changed
Net revenue increased $71.7 $100.6 million, or 12.0%, 13.0%, for the year ended December 31, 2023 2025 compared to the same period in 2022. The growth 2024. Driving this increase was our 47 new stores opened in net revenue was primarily driven by an 2025, a 7.0% increase in our Active Customers, and a 5.7% increase in Average Revenue per Customer, Customer to $287 $324, from $263 $307 in the prior year period, as well as a 2.5% increase in Active Customers. period. Average Revenue per Customer growth was primarily driven by an increase our glasses business, which benefited from strong adoption of precision progressives and selective price increases during the second quarter, as well as by growth in units per order as customers took advantage of our bundling promotions contacts and also eye exam businesses which are often purchased contacts or eye exams along together with glasses in the same transaction. glasses.
Paragraph 98 · 32% changed
Inventory is stated at the lower of cost or net realizable value, with cost determined on a weighted average cost basis. We continuously evaluate the composition of our inventory and make adjustments when the cost of inventory is not expected to be fully recoverable. The estimated net realizable value of excess and obsolete inventory is determined based on an analysis of historical sales trends, the impact of market trends and economic conditions, forecasts of future demand, and estimated timing of product retirements. Adjustments for damaged inventory are recorded primarily based on actual damaged inventory. Adjustments for inventory shrink, representing the physical loss of inventory, are estimated based on historical experience and are adjusted based upon physical inventory counts. Actual results may differ from estimates due to the quantity and mix of products in inventory, consumer preferences, and economic and market conditions. Our historical estimates of these costs and the related provisions have not differed materially from actual results. However, unforeseen adverse future economic and market conditions, such as those resulting from disease pandemics and other catastrophic events, could result in our actual results differing materially from our estimates.
Paragraph 60 · 28% changed
Selling, general, and administrative expenses increased $19.7 $19.0 million, or 4.5%, 4.2%, for the year ended December 31, 2024 2025 compared to the same period in 2023. 2024. This increase was primarily driven by higher payroll-related costs, primarily payroll related costs from growth in our retail workforce, workforce and investments in marketing, partially offset by a $23.2 million decrease in lower stock-based compensation, mostly related to the Founders Grant (as described in Note 7 to our consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K).
Paragraph 44 · 25% changed
(5) Represents employee severance Primarily represents restructuring costs incurred in the second quarter of 2025 and related costs for restructuring actions executed in October the fourth quarter of 2024 and August 2022 and charges for certain legal matters outside the ordinary course of business.
Paragraph 58 · 25% changed
Gross margin, expressed as a percentage and calculated as gross profit divided by net revenue, decreased by 250 130 basis points for the year ended December 31, 2023 2025 compared to the same period in 2022. 2024. The decrease in gross margin was primarily driven by the tariff costs related to glasses, sales growth of contact lenses lenses, which are sold at a lower margin than our other eyewear, increased doctor salaries, headcount as the number of exam stores offering eye exams grew, grew by 21%, and increases in store occupancy costs as a percent of revenue as we grew our store base from 200 stores as of December 31, 2022 to 237 stores as of December 31, 2023. These impacts were partially offset by increased progressives penetration, increased efficiencies in our owned optical laboratories, and lower outbound customer shipping costs as a percent of revenue. revenue, partially offset by selective price increases in glasses taken in the second quarter and increased penetration of progressives and other lens enhancements.
Paragraph 21 · 25% changed
In addition to the measures presented in our consolidated financial statements, we use the following key business metrics and certain non-GAAP financial measures to evaluate our business, measure our performance, develop financial forecasts, and make strategic decisions. The following table summarizes our key performance indicators and non-GAAP financial measures for the periods presented, which are unaudited.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors331 words changed in this paragraph; it is 30% similar to last year's version.
Meeting customer demand partially depends on our ability to obtain timely and adequate delivery of components for our products and services. All of the components that go into the manufacturing of our products and services are sourced from a limited number of third-party suppliers predominantly in the U.S., China, Italy, Vietnam, and Japan, and, in particular, over around half of the cellulose acetate used to produce many of our frames is provided by a single supplier. Aside from the cellulose acetate that we source ourselves, our Our contract manufacturers purchase many of these components on our behalf, including sun lenses, demo lenses, hinge and core kits, and branded logos, subject behalf. For our business to certain approved supplier lists, and we do not have long-term arrangements with most of our component suppliers. We are therefore subject to the risk of shortages and long lead times in the supply of these components and the risk that be successful, our suppliers discontinue or modify components used in our products. In addition, the lead times associated with certain components are lengthy must be willing and preclude rapid changes in design, quantities, and delivery schedules. Our ability to meet temporary unforeseen increases in demand has been, and may in the future be, impacted by our reliance on the availability of components from these sub-suppliers. We may in the future experience component shortages, and the predictability of the availability of these components may be limited, which may be heightened in the event of global supply chain disruption. In the event of a component shortage or supply interruption from suppliers of these components, we may not be able to develop alternate sources provide us with inputs in a timely manner. Developing alternate sources of supply for these components may be time-consuming, difficult, and costly, and we may not be able to source these components on terms that are acceptable to us, or at all, which may undermine our ability to fill our orders substantial quantities, in a timely manner. Any interruption or delay in the supply of any of these parts or components, or the inability to obtain these parts or components from alternate sources at acceptable prices and within a reasonable amount of time, would harm our ability to timely ship our products to our customers. See “—We face risks associated compliance with suppliers from whom our products are sourced and are dependent on a limited number of suppliers.”

Source: Item 1A, 10-K 0001504776-26-000006 vs Item 1A, 10-K 0001504776-25-000010

MD&A171 words changed in this paragraph; it is 36% similar to last year's version.
The nature of our business, which involves the sale of products and services that are a medical necessity for many consumers, provides some insulation from swings in consumer sentiment and general economic conditions. sentiment. However, our performance and growth are still subject to broader macroeconomic factors. During 2025, we experienced pressure from a dynamic trade environment and fluctuating inflationary trends, which impacted by these factors. Elevated inflation and interest rates, tariffs, and other negative economic factors may impact both consumer discretionary spending habits as well as our cost of attracting and our ability internal cost structure. While elevated interest rates and government policy continue to attract new customers. We believe our business model, influence consumer confidence, we remain focused on providing an exceptional our core value and experience proposition to our customers, will help mitigate the impact of many of these macroeconomic factors, however, the extent of such mitigation and the impact on future results is uncertain. We also continue to diversify and expand our supply chain network, both internationally with our frame manufacturers and domestically with our wholly owned and partner optical laboratories, which we believe helps to insulate us from supply chain disruption and allowed us to continue to meet growing customer demand over the last several years while maintaining our exceptional quality and customer satisfaction standards. headwinds.

Source: Item 7, 10-K 0001504776-26-000006 vs Item 7, 10-K 0001504776-25-000010

Accounting Policies71 words changed in this paragraph; it is 67% similar to last year's version.
Stock-based compensation is recorded as a component of both cost of goods sold and or selling, general, and administrative expenses and follows in the classification same manner as the compensation costs of the related employee. employees. The Company recognizes compensation expense for stock-based awards based on the grant date fair value, on either (i) a straight-line basis for awards with only a service condition, or (ii) an accelerated attribution basis for awards with a performance condition, over the requisite service period of the awards, which is generally the vesting term of the outstanding stock awards. Compensation expense for awards with a performance condition is recognized when it is determined that it is probable that the vesting conditions will be satisfied. The Company utilizes a narrow interpretation of award authorization and expense and stock-based compensation expense is recognized beginning on an award’s grant date.

Source: Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001504776-26-000006 vs Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001504776-25-000010

Legal Proceedings60 words changed in this paragraph; it is 67% similar to last year's version.
The 2024 Credit Facility contains a financial maintenance covenant which only applies while total borrowings exceed $30.0 million, which requires the Company to maintain a maximum consolidated senior net leverage ratio of 3:1. The 2024 Credit Facility contains customary affirmative and negative covenants, including limits on indebtedness, liens, capital expenditures, asset sales, investments and restricted payments, in each case subject to negotiated exceptions and baskets, as well as customary representations, warranties and event of default provisions. The obligations of the Borrowers under the 2024 Credit Agreement are secured by first-lien security interests in substantially all of the assets of the Borrowers. In addition, the obligations are required to be guaranteed in the future by certain additional domestic subsidiaries of the Company.

Source: Item 3, via Note 11 – Commitments and Contingencies, 10-K 0001504776-26-000006 vs Item 3, via Note 11 – Commitments and Contingencies, 10-K 0001504776-25-000010

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of WRBY's Risk Factors and MD&A, 10-K Feb 26, 2026 against 10-K Feb 27, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
economic conditions and global events, such as geopolitical conflicts, natural disasters, or public health crises, may disrupt our supply chain, potentially preventing us from procuring timely deliveries or securing comparable alternatives at acceptable prices.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
Our use of artificial intelligence may result in operational disruptions, reputational harm, competitive challenges, regulatory scrutiny, liability, or security risks that could adversely affect our business, financial condition, and results of operations.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
Our success will depend, in part, on our ability to expand our services and grow our business in response to changing technologies, customer demands, and competitive pressures. We have and may continue to expand our services and grow our business by entering into partnerships or alliances with third parties. For example, we have recently partnered with Target Corporation to open shop-in-shop stores within select Target locations, and we are partnering with Google and Samsung to develop AI-powered smart glasses. Certain of our partnerships are, and may in the future be, with partners that have significant size, scale, geographic, and other advantages over us. As a result, certain of the terms in such partnerships may be less favorable to us compared to partnerships with other parties. Any of our partnerships may not lead to the business, growth, and financial outcomes that we expect, may raise new obligations and challenges, may divert the attention of management, and may also result in higher costs for us or other negative impacts to our business, operations, regulatory posture, or strategy, which we may not anticipate or currently project, that result in a material adverse effect to our business, financial condition, and results of operations. These partnerships can require several agreements to be entered into over time following the initial partnership agreement. In addition, these partnerships may span multiple years and may require significant upfront costs. As a result, we may not be able to accurately assess the success of these partnerships for several periods and only after we have made substantial
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
investments and expenditures. If any partnership results in future material adverse effects to our business, financial condition, and results of operations, we may not be able to terminate such partnership on a timely or cost-effective basis and termination may result in loss of certain rights related to the partnership and the products or services subject to the partnership. If any such partnerships are terminated or any of our partners refuse to renew their agreements with us on commercially reasonable terms, we may not be able to secure similar terms or replace such partners in an acceptable time frame. Additionally, certain of our partnerships depend or may in the future depend on the achievement of certain milestones. We may not achieve such milestones, which would impact our ability to realize some or all of the benefits of such partnerships.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
campaigns and litigation, to advance their perspectives. To the extent we are subject to such activism, it may require us to incur costs or otherwise adversely impact our business.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
example, we have registrations in a number of foreign countries in which we are not currently offering products or services, and those registrations could be subject to invalidation proceedings if we cannot demonstrate use of the marks by the applicable use deadlines in those countries.
Read it in 10-K Feb 26, 2026 at sec.gov
Show the other 59
AddedRisk Factors
We use third-party open-source software in connection with the development and deployment of our software applications. From time to time, companies that use third-party open-source software have faced claims challenging the use of such open-source software and their compliance with the terms of the applicable open-
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
All of the components that go into the manufacturing of our products and services are sourced from a limited number of third-party suppliers predominantly in the U.S., China, Italy, Vietnam, and Japan, and, in particular, around half of the cellulose acetate used to produce many of our frames is provided by a single supplier. Our contract manufacturers purchase many of these components on our behalf. For our business to be successful, our suppliers must be willing and able to provide us with inputs in substantial quantities, in compliance with
Read it in 10-K Feb 26, 2026 at sec.gov
RemovedRisk Factors
•successfully compete with other companies that are currently in, or may in the future enter, the industry or the markets in which we compete, and respond to developments from these competitors such as pricing changes and the introduction of new products and services;
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
•successfully expand and gain market adoption on our market share by offering customers the ability to pay through managed vision care, vision insurance, and other third-party payors;
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
•successfully develop new offerings, including new offerings with higher margins, and innovate and enhance our existing products and services and their features, including in response to new trends, competitive dynamics, or the needs of customers;
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
Because we have a limited history operating our business at its current scale, it is difficult to evaluate our current business and future prospects, including our ability to plan for and model future growth. Our limited operating experience at this scale, combined with the rapidly evolving nature of the market in which we sell our products and services, substantial uncertainty concerning how these markets may develop, and other economic factors beyond our control, reduces our ability to accurately forecast quarterly or annual revenue. Failure to manage our future growth effectively could have an adverse effect on our business, financial condition, and operating results.
Read it in 10-K Feb 27, 2025 at sec.gov
RewordedRisk Factors
Moreover, the vertically integrated nature of our business, where we design all of our own glasses in our New York headquarters, contract manufacture all of our glasses frames, fulfill the glasses we sell at our own optical and fulfillment laboratories as well as at third-party contract laboratories, sell our products exclusively through our own retail stores, e-commerce site and mobile application, and service our products, business exposes us to risk and disruption at many points that are critical to successfully operating our business, and may make it more difficult for us to scale our business.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
There is also no guarantee that our pending trademark applications for any mark will proceed to registration; our Our pending applications may be opposed by a third party parties prior to registration; registration, and even those our registered trademarks that are registered could be challenged by a third party, including by way of revocation or invalidity actions. parties.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Any provision in our certificate of incorporation, our bylaws, or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our Class A common stock, and could also affect the price that some investors are willing to pay for our Class A common stock.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
In addition, the FDA may change its policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay marketing authorization of our products (or modifications to our products), may increase the costs of compliance, or impact otherwise adversely affect our ability to modify any products for which we or our third-party manufacturers have already obtained marketing authorizations on a timely basis. business.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
In recent years, the U.S. government has implemented tariffs on specified products imported into the United States from China and, as a result, costs with respect to our products subject to these in 2025, the U.S. government announced new or heightened tariffs have increased. on product imports from certain countries, including China, Italy, Vietnam and Japan.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
We rely heavily on our information technology systems, as well as those of our third-party vendors, business partners, and service providers, for our business to effectively operate and to safeguard confidential information; any Any significant failure, inadequacy, interruption, or cybersecurity incident could adversely affect our business, financial condition, and operations.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Despite our precautions, it may be possible for unauthorized third parties to copy our offerings and capabilities and use information that or to register our trademarks or other trademarks similar to our trademarks in jurisdictions before we regard as proprietary do, leading to create offerings that compete with ours. brand confusion or dilution.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
For example, as discussed above, in 2018, we experienced a credential stuffing attack attack, in which malicious third parties used credentials compromised in data breaches suffered by other companies to access accounts on our platform platform, and received notice that OCR the Office for Civil Rights (“OCR”) would be investigating the incident and our compliance with the Privacy, Security, and Breach Notification Rules and requesting certain information related to the incident and our compliance with the Privacy, Security, and Breach Notification Rules.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
As and if To the extent we expand our operations into new geographies, the scale effects of our international business activities, any changes being subject to taxation in the United States or foreign taxation of such activities jurisdictions may increase our worldwide effective tax rate and harm our business, financial condition, and results of operations.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
The As a public company, we are subject to the reporting requirements of these the Exchange Act, the listing standards of the NYSE, and other applicable securities rules and regulations regulations, which have increased and will likely continue to increase our legal, accounting, and financial compliance costs, make some activities more difficult, time-consuming and costly, and place significant strain on our personnel, systems, and resources.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Increases in component costs, shipping costs, long lead times, supply shortages, and supply changes could disrupt Disruptions to our supply chain and factors such as wage rate increases and inflation can have a material adverse effect on our business, financial condition, and operating results.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
We continuously evaluate our systems landscape landscape, and we may have to upgrade been undertaking a multi-year process of upgrading our IT systems or implement new technology systems from time to time systems, including our ERP system, in order to support the needs of our business.
Read it in 10-K Feb 26, 2026 at sec.gov
Quiet changesRisk Factors
In several many states where we operate, state corporate practice of medicine and optometry laws prohibit a business corporation from practicing medicine or optometry, directly employing physicians or optometrists to provide professional services, or exercising control over treatment decisions by such professionals.
Read it in 10-K Feb 26, 2026 at sec.gov
Quiet changesRisk Factors
Litigation brought to protect and enforce our intellectual property rights could be costly, time-consuming, and distracting to management, may not be successful, and could result in the impairment or loss of portions of our intellectual property rights.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
In the second quarter of 2025, we announced a partnership with Google to develop AI-enabled glasses intended for all-day wear. We are working closely with Google on the development of AI glasses and intend to launch a series of products over time. As part of this collaboration, Google has committed up to $75 million for our product development and commercialization costs. In addition, Google has committed to investing up to $75 million in Warby Parker, at our option and subject to reaching certain collaboration milestones. During the year ended December 31, 2025, the Company reduced selling, general, and administrative expenses by $3.3 million related to costs which are reimbursable by Google and are thus fully offset within the period.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
The nature of our business, which involves the sale of products and services that are a medical necessity for many consumers, provides some insulation from swings in consumer sentiment. However, our performance and growth are still subject to broader macroeconomic factors. During 2025, we experienced pressure from a dynamic trade environment and fluctuating inflationary trends, which impacted both consumer discretionary spending and our internal cost structure. While elevated interest rates and government policy continue to influence consumer confidence, we remain focused on our core value proposition to mitigate these headwinds.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
Our 2025 results were affected by cost volatility related to evolving international trade policies and tariffs. We have taken proactive steps to manage these costs, including further diversifying our supplier base outside of China, making strategic price adjustments on select products, and disciplined expense management. The complexity of the global trade landscape makes it difficult to predict the timing and extent of future policy changes.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
We believe our business model, which emphasizes an outstanding value-driven experience, provides a durable foundation. Our ongoing efforts to expand our supply chain network, both through international frame manufacturing partnerships and our domestic optical laboratories, are a key strategy intended to insulate us from localized disruptions. While we continue to navigate these macroeconomic uncertainties, we remain committed to meeting growing customer demand while maintaining our exceptional quality and customer satisfaction standards.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
compensation, mostly related to the 2021 Founders Grant. As a percentage of revenue, SG&A decreased by 460 basis points, primarily driven by slower growth in corporate expenses, efficiencies in our customer experience operations, and reduced stock-based compensation.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
In February 2026, the Company’s Board of Directors authorized a share repurchase program to purchase up to $100.0 million of the Company’s Class A common stock (the “Share Repurchase Program”). Repurchases under the Share Repurchase Program may be made in the open market, in privately negotiated transactions, or otherwise, with the amount and timing of repurchases to be determined at the Company’s discretion, depending on market conditions and corporate needs. Open market repurchases will be structured to occur in accordance with applicable federal securities laws, including within the pricing and volume requirements of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The Company may also, from time to time, enter into Rule 10b5-1 plans to facilitate repurchases of its shares under this authorization. The Share Repurchase Program does not have a fixed expiration date, does not obligate the Company to acquire any
Read it in 10-K Feb 26, 2026 at sec.gov
RemovedMD&A
The nature of our business, which involves the sale of products and services that are a medical necessity for many consumers, provides some insulation from swings in consumer sentiment and general economic conditions. However, our performance and growth are still impacted by these factors. Elevated inflation and interest rates, tariffs, and other negative economic factors may impact consumer spending habits as well as our cost of attracting and our ability to attract new customers. We believe our business model, focused on providing an exceptional value and experience to our customers, will help mitigate the impact of many of these macroeconomic factors, however, the extent of such mitigation and the impact on future results is uncertain. We also continue to diversify and expand our supply chain network, both internationally with our frame manufacturers and domestically with our wholly owned and partner optical laboratories, which we believe helps to insulate us from supply chain disruption and allowed us to continue to meet growing customer demand over the last several years while maintaining our exceptional quality and customer satisfaction standards.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
We recognize compensation expense for stock-based awards based on the grant date fair value, on a straight-line basis over the requisite service period of the awards, which is generally the vesting term of the outstanding stock awards. Compensation expense for performance awards is recognized when it is determined that it is probable that the vesting conditions will be satisfied.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
In June 2021, we granted 4,397,688 PSUs and 1,884,724 RSUs to the Co-CEOs, in the aggregate, under the 2019 Plan (the “Founders Grant”). The PSUs vest upon two performance conditions, (i) a qualified public offering and (ii) the price of our Class A common stock reaches stock price hurdles over a period of ten years, as defined by the terms of the award. The PSUs are subject to the Co-CEOs’ continued employment with the Company through the applicable vesting date.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
We used a Monte Carlo simulation to calculate the grant-date fair value of the PSUs of $128.8 million. Since the PSUs contain a performance and market condition, the stock-based compensation expense is recognized when it becomes probable that the performance condition will be met using the accelerated attribution method. Stock-based compensation is recognized over the period of time the market condition for each tranche is expected to be met (i.e., the derived service period). The derived service period over which the expense is expected to be recognized is 3.8 years. The qualified public offering performance condition was satisfied at September 29, 2021 by our direct listing, and we began recording expense at that time.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
The Founders Grant RSUs vest in equal monthly installments over a period of five years, subject to the Co-CEOs’ continued employment with the Company through the applicable vesting date and conditioned upon the completion of a qualified public offering. The grant-date fair value of the RSUs is $66.9 million. Since the RSUs contain a performance condition, stock-based compensation expense is recognized using the accelerated attribution method when it becomes probable that the performance condition will be met. The performance condition was satisfied on September 29, 2021 by our direct listing, and we began recording expense at that time.
Read it in 10-K Feb 27, 2025 at sec.gov
RewordedMD&A
The decrease in gross margin was primarily driven by the tariff costs related to glasses, sales growth of contact lenses lenses, which are sold at a lower margin than our other eyewear, increased doctor salaries, headcount as the number of exam stores offering eye exams grew, grew by 21%, and increases in store occupancy increased customer shipping costs as a percent of revenue as we grew our store base from 200 stores as revenue, partially offset by selective price increases in glasses taken in the second quarter and increased penetration of December 31, 2022 to 237 stores as of December 31, 2023. progressives and other lens enhancements.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
This increase was primarily driven by higher payroll-related costs, primarily payroll related costs from growth in our retail workforce, workforce and investments in marketing, partially offset by a $23.2 million decrease in lower stock-based compensation, mostly related to the Founders Grant (as described in Note 7 to our consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K).
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
The increase in cost of goods sold was primarily driven by increased product and fulfillment costs associated with our sales growth, particularly related to the growth in our contact lens offering, as well as increases in store occupancy, store depreciation, doctor headcount due to new retail stores opened in 2024, offering and optical laboratory costs to support glasses growth. growth, as well as increases in store occupancy costs and doctor headcount due to new retail stores.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Interest and other income, net (8,379) (10,596) (9,232) (1,307) Provision for income taxes 1,402 875 433 497 Depreciation and amortization expense 50,280 45,865 38,554 31,864 Asset impairment charges 557 816 3,230 1,647 Stock-based compensation expense(1) 36,097 48,409 71,065 98,655 Non-cash charitable donations(2) 2,821 2,196 3,191 3,770 Amortization of cloud-based software implementation costs(3) costs 3,405 3,704 2,895 247 ERP System implementation costs(4) costs(3) 1,883 — 4,413 687 Inventory write-downs(4) 2,456 — — Other costs(5) 3,048 2,232 1,000 1,535 Adjusted EBITDA $ 95,211 $ 73,111 $ 52,352 $ 27,202 Adjusted EBITDA Margin 10.9 % 9.5 % 7.8 % 4.5 %
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
The changes in operating assets and liabilities were primarily driven by decreased inventory as we more closely manage stock on hand, increased accrued expenses, increases in accounts payable and increased net lease liabilities and a decrease in connection with retail leases entered into in 2024, inventory, partially offset by an increase in prepaid expenses and other current assets.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
For the year ended December 31, 2024, 2025, net cash provided by used in financing activities was $5.0 $12.0 million, which was primarily related to cash paid for shares withheld for taxes for stock-based compensation, partially offset by proceeds from stock option exercises, shares issued in connection with our Employee Stock Purchase Plan (“ESPP”), and other equity activity. (“ESPP”).
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
(5) Represents employee severance Primarily represents restructuring costs incurred in the second quarter of 2025 and related costs for restructuring actions executed in October the fourth quarter of 2024 and August 2022 and charges for certain legal matters outside the ordinary course of business.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
(2) Represents charitable expense recorded in connection with the donation of 178,572 shares of Class A common stock in each of May 2025, May 2024, and August 2023 and May 2022 to the Warby Parker Impact Foundation, and 56,938 shares of Class A common stock to charitable donor advised funds in June 2023, and 34,528 shares of Class A common stock to charitable donor advised funds in November 2022. 2023.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
(1) Represents expenses related to the Company’s equity-based compensation programs and related employer payroll taxes, which may vary significantly from period to period depending upon various factors including the timing, number, and the valuation of awards granted, and vesting of awards including the satisfaction of performance conditions, as well as the issuance of 48,486 shares of Class A common stock to charitable donor advised funds in February 2024. conditions.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Provision for income taxes increased $0.4 $0.5 million, or 102.1%, 60.2%, for the year ended December 31, 2024 2025 compared to the same period in 2023 2024 primarily due to the change in pre-tax loss income (loss) in addition to the tax effects of stock-based compensation expense, expense and depreciation expense, and differences in tax rates in state jurisdictions. expense.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Net revenue 100.0% 100.0% 100.0% Cost of goods sold 46.0% 44.7% 45.5% 43.0% Gross profit 54.0% 55.3% 54.5% 57.0% Selling, general, and administrative expenses 54.6% 59.2% 65.3% 75.6% Loss from operations (0.6)% (3.9)% (10.8)% (18.6)% Interest and other income, net 1.0% 1.4% 1.4% 0.2% Loss Income (loss) before income taxes 0.4% (2.5)% (9.4)% (18.4)% Provision for income taxes 0.2% 0.1% —% 0.1% Net loss income (loss) 0.2% (2.6)% (9.4)% (18.5)%
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Year Ended December 31, 2025 2024 2023 2022 ($ in thousands) Net cash provided by operating activities $ 110,785 $ 98,744 $ 60,991 $ 10,370 Net cash used in investing activities (67,048) (66,032) (54,671) (60,181) Net cash (used in) provided by financing activities 4,961 (11,997) 4,959 2,871 3,291 Effect of exchange rates on cash 457 (404) (882) (1,311) Net increase (decrease) in cash and cash equivalents $ 32,197 $ 37,267 $ 8,309 $ (47,831)
Read it in 10-K Feb 26, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/WRBY/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.